

COVID-19 Vaccination: Where Do We Stand?

Additional Resources

The following resources were shared during the live session:

- Post session resources (podcast of webinar, presentation slides, responses to unanswered questions) can be found on our website next week:
 - <https://med.emory.edu/departments/medicine/divisions/infectious-diseases/serious-communicable-diseases-program/covid-19-resources/access-past-echo-recordings.html>
- Register for upcoming sessions on our website:
 - <https://med.emory.edu/departments/medicine/divisions/infectious-diseases/serious-communicable-diseases-program/covid-19-resources/echo-upcoming-session.html>
- Vaccine Booster Scheduling Tool
 - <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html>
- Benefit to infants through 6 months of life exist from maternal COVID vaccination.
 - Good MMWR article to help emphasize this with your pregnant patients:
 - Title: Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022
 - DOI: 10.15585/mmwr.mm7107e3

Session Recap:

- Situational Report:




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: WHO Health Emergencies Programme
Map Date: 21 May 2022



- Special Pathogen of Concern - Monkey Pox:

- May 24, 2022: Outbreak continues to evolve, with significant spread continuing in endemic west African countries. There are now 156 confirmed cases in 16 countries, 12 of which are non-endemic regions. In those countries no deaths have been reported to date and no travel links have been elucidated.



- In the US, there have been 4 confirmed cases – one each in Regions 1,2,9, and 10; and in region 8 there are currently at least 2 persons under investigation.



- May 22, 2022: In region 4, The Emory University Serious Communicable Diseases Unit (SCDU) was fully activated for a high risk PUI. The patient was eventually found to have an alternative diagnosis and SCDU was deactivated one day later. Currently there remains one active PUI in the Region and SRDRS and SCDU teams remain on alert. The threat to the general public remains low.

Common Questions During Session:

- Do you foresee vaccine manufacturers producing multivalent vaccines anytime soon?
 - There will be discussions at the end of June at VRBPAC and WHO will be having separate discussions about the topic of variant vaccines and benefit of variant or multivalent vaccines. It is likely that some guidance will come from this. Manufacturer capacity is great, but would take at least a little bit of time to shift over from prototype vaccine.
- Any idea about other vaccine formulations timeline - Anofi and Novavax?
 - Novavax appears to have some problems with ramping up their production. Uncertain what will happen with this vaccine in the US. Sanofi released positive results from their Phase 3 study, mostly conducted outside the US. It is anticipated that they will go to FDA for EUA and will be conducting boost studies. Timeline for them submitting to FDA is not publicly known.
- Do you foresee a vaccine for influenza and Covid-19 together?
 - Seasonal influenza vaccination will continue to be critical, particularly as we move out of the social measure era. One might expect a big influenza season next season. It will also be important to ensure that people are fully COVID vaccinated and boosted as recommended. There are ongoing studies of mRNA influenza vaccination that may

ultimately result in influenza mRNA vaccination (but likely to be at least several years away). One could envision that COVID-19 and influenza mRNA vaccination could be co-formulated ultimately.